Repligen Corporation $RGEN Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 19.4% in the first quarter, HoldingsChannel.com reports. The fund owned 159,745 shares of the biotechnology company’s stock after selling 38,459 shares during the quarter. Principal Financial Group Inc.’s holdings in Repligen were worth $18,821,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in RGEN. Diversify Wealth Management LLC boosted its position in Repligen by 56.8% during the 1st quarter. Diversify Wealth Management LLC now owns 13,616 shares of the biotechnology company’s stock valued at $1,540,000 after purchasing an additional 4,933 shares during the period. Hsbc Holdings PLC lifted its position in Repligen by 844.7% in the 1st quarter. Hsbc Holdings PLC now owns 19,772 shares of the biotechnology company’s stock valued at $2,308,000 after purchasing an additional 17,679 shares during the last quarter. Granite Investment Partners LLC boosted its stake in Repligen by 36.1% during the 1st quarter. Granite Investment Partners LLC now owns 4,001 shares of the biotechnology company’s stock valued at $471,000 after purchasing an additional 1,061 shares during the period. Oregon Public Employees Retirement Fund grew its position in Repligen by 2.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 10,841 shares of the biotechnology company’s stock worth $1,277,000 after purchasing an additional 300 shares during the last quarter. Finally, Stephens Inc. AR increased its stake in shares of Repligen by 3.0% in the first quarter. Stephens Inc. AR now owns 48,376 shares of the biotechnology company’s stock valued at $5,700,000 after purchasing an additional 1,390 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen News Roundup

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen agreed to buy BioLife Solutions in a cash-and-stock transaction valued at about $1.5 billion, adding BioLife’s biopreservation media and cell processing tools to Repligen’s portfolio and broadening its exposure to cell therapy. Article Title
• Positive Sentiment: Management said the deal should be accretive to revenue growth, margins, and adjusted EPS, with at least $20 million of synergies in year one and $30 million in year two, which supports the investment case for long-term earnings growth. Article Title
• Neutral Sentiment: The purchase price includes both cash and Repligen shares, so while the acquisition could create growth opportunities, investors may also be weighing potential dilution and integration risk until the deal closes, which is expected in Q4 2026. Article Title
• Negative Sentiment: Some commentary suggests the market may be cautious on the acquisition price and deal structure, with one analyst note on BioLife saying the transaction caps upside, reflecting some skepticism around valuation and near-term execution. Article Title

Repligen Stock Up 2.3%

RGEN stock opened at $140.09 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The firm has a market capitalization of $7.90 billion, a P/E ratio of 155.66, a P/E/G ratio of 2.64 and a beta of 1.06. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The company’s 50 day simple moving average is $130.41 and its 200-day simple moving average is $132.79.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.25 million for the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities research analysts anticipate that Repligen Corporation will post 1.99 EPS for the current year.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on RGEN. Royal Bank Of Canada began coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective for the company. Canaccord Genuity Group decreased their price target on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. JPMorgan Chase & Co. cut their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Evercore reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a report on Monday, July 6th. Finally, Jefferies Financial Group restated a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $165.36.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.